--- url: 'https://qubit.capital/blog/europe-series-a-weekly-funding-roundup-week-2-april-2026' title: 'Europe Series A Weekly Funding Roundup (Apr 7-14, 2026): $72.0M Raised Across 2 Deals' author: name: Sagar Agrawal url: 'https://qubit.capital/blog/author/sagar' date: '2026-04-14T06:18:07+05:30' modified: '2026-04-14T11:32:01+05:30' type: post summary: 'Two European Series A rounds totaling $72M: Berlin''s Midas raises $50M for tokenized investment products, Paris-based Generare secures €20M for microbial drug discovery.' categories: - Weekly Funding Roundup image: 'https://qubit.capital/wp-content/uploads/2026/04/featured-europe-series-a-65709.webp' published: true --- # Europe Series A Weekly Funding Roundup (Apr 7-14, 2026): $72.0M Raised Across 2 Deals European Series A activity this week centered on two companies turning regulated complexity into competitive advantage. A Berlin-based tokenization platform and a Paris-based drug discovery outfit raised a combined $72 million, each attacking markets where deep technical and regulatory barriers keep most competitors out. Both rounds share a common thread: founders with institutional pedigrees building platforms that generate compounding data assets. Midas wraps traditional finance products in DeFi-native wrappers under strict EU regulation, while Generare mines billions of years of microbial evolution for molecules no AI model has ever seen. Neither is chasing hype cycles. They’re building moats that get wider with every transaction processed and every compound characterized. Weekly Funding Roundup APR 7-14, 2026 $70M TOTAL RAISED 2DEALS CLOSED 100%SERIES A $35MAVG DEAL SIZE EUROPETOP REGION BY STAGE Series A$70M100% BY SECTOR MidasFintech / Tokenization$50M GenerareHealthtech / Drug Discovery$20M Table of Contents - [1. Midas Raises $50M For Tokenized Investment Products](#1-midas-raises-$50m-for-tokenized-investment-products) [Deal Overview](#deal-overview) - [Investor Profile](#investor-profile) - [Company and Leadership](#company-and-leadership) - [Problem and Opportunity](#problem-and-opportunity) - [Product and Technology](#product-and-technology) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision) - [Market Context](#market-context) - [2. Generare Raises €20M For Microbial Drug Discovery](#2-generare-raises-€20m-for-microbial-drug-discovery) [Deal Overview](#deal-overview-1) - [Investor Profile](#investor-profile-1) - [Company and Leadership](#company-and-leadership-1) - [Problem and Opportunity](#problem-and-opportunity-1) - [Product and Technology](#product-and-technology-1) - [Use of Proceeds and Vision](#use-of-proceeds-and-vision-1) - [Market Context](#market-context-1) - [Lessons For Founders](#lessons-for-founders) ## 1. Midas Raises $50M For Tokenized Investment Products ### Deal Overview - **Stage:** Series A - **Sector:** Fintech / Tokenization - **Geography:** Berlin, Germany - **Round Size:** $50M (total raised: $58.75M) - **Valuation:** Not disclosed ### Investor Profile The round drew twelve investors spanning traditional finance and crypto-native capital. RRE Ventures and Creandum co-led, with Franklin Templeton and Coinbase Ventures joining as strategic backers. Framework Ventures, Anchorage Digital, HV Capital, Ledger Cathay, North Island Ventures, M1 Capital, FJ Labs, and GSR filled out the syndicate. When a $1.5 trillion asset manager and the largest US crypto exchange both write checks into the same Series A, it signals that the line between TradFi and DeFi is disappearing faster than most people realize. ### Company and Leadership [Midas](https://www.midas.app) was founded in 2023 by Dennis Dinkelmeyer, Fabrice Grinda, and Romain Bourgois. Dinkelmeyer is a former Goldman Sachs operator. Grinda is a serial entrepreneur who co-founded OLX and runs FJ Labs, one of the most active angel funds globally. Bourgois came from Ondo Finance and Criteo, bringing experience across both DeFi protocols and scaled ad-tech platforms. The team shipped their product in 2024, just a year after founding. ### Problem and Opportunity Institutional investment strategies remain locked behind accredited investor gates, custodial intermediaries, and multi-day settlement windows. Retail investors in Europe can buy ETFs but can’t access the same treasury bill or basis trading strategies available to institutions. DeFi protocols offer composability and speed but lack regulatory clarity and institutional-grade risk management. Midas sits in the gap between these two worlds. ### Product and Technology Midas packages institutional strategies into regulatory-compliant ERC-20 tokens that plug directly into DeFi protocols. Their flagship product, mTBILL, tracks short-dated US Treasury Bills through a BlackRock-managed fund as a permissionless on-chain token. mBASIS tokenizes a market-neutral crypto basis trading strategy. The company built MSL, a $40M dedicated liquidity layer that enables instant atomic redemptions, solving the biggest pain point in tokenized funds: getting your money out quickly. The platform is BaFin-regulated and MiCA-compliant, meaning it can distribute to retail investors across the EU. So far, $1.7 billion in assets have been issued and $37 million in yield distributed to over 20,000 token holders. ### Use of Proceeds and Vision The $50M will scale the MSL liquidity facility, build new asset classes including reinsurance-linked securities and receivables strategies, deepen integrations with DeFi protocols like Morpho and Pendle, and expand across European markets. The founding team’s stated ambition is to make investing “work like the internet: open, transparent, composable, and accessible by default.” ### Market Context Global tokenized real-world assets crossed $12 billion by March 2026, doubling from $5 billion in early 2025. VC deployment into crypto and blockchain hit $3.1 billion in March 2026 alone, concentrated heavily in RWA infrastructure. MiCA regulation going live across Europe creates a window where compliant platforms gain distribution advantages that take years for competitors to match. Midas is one of the first tokenized fund platforms accessible to non-accredited retail investors in Europe, and that regulatory head start compounds with every month of compliance history. ## 2. Generare Raises €20M For Microbial Drug Discovery ### Deal Overview - **Stage:** Series A - **Sector:** Healthtech / Drug Discovery - **Geography:** Paris, France - **Round Size:** €20M (~$22M; total raised: ~€25M) - **Valuation:** Not disclosed ### Investor Profile Alven and Daphni led the round, joined by returning investors Galion.exe, Teampact Ventures, and VIVES Partners. All three seed investors doubled down, which tells you something about what they’ve seen since their initial €5M bet in October 2024. Alven has a strong track record in French deep tech, having backed companies like Dataiku before its $4.6 billion valuation. Daphni brings a community-driven investment model with particular strength in life sciences. ### Company and Leadership [Generare](https://www.generare.bio) was founded in 2023 by Guillaume Vandenesch and Dr. Vincent Libis. Vandenesch brings commercial experience in synthetic biology. Libis is the scientific engine: a decade of synthetic biology research, ERC grant funding, co-founder of Abolis Biotechnologies, former researcher at Rockefeller University, and INSERM team leader. The company has grown to about 25 people and plans to nearly double. ### Problem and Opportunity Drug discovery AI has a data problem. The models are powerful, but they’re trained on a narrow slice of known chemistry. Roughly 97% of microbial genomic chemistry has never been explored. That means billions of years of evolution have produced molecular structures that no database contains and no algorithm has seen. Penicillin, rapamycin, vancomycin, erythromycin: over 500 FDA-approved drugs trace back to microbial chemistry. The problem isn’t that we’ve run out of molecules. It’s that we stopped looking in the right places. ### Product and Technology Generare runs a four-step industrial process. First, they screen tens of thousands of microbial genomes at scale. Second, they identify biosynthetic gene clusters most likely to produce bioactive molecules. Third, they express those sequences in controlled lab conditions. Fourth, they characterize the resulting compounds for structure, biological activity, and drug potential. In 2025, the team identified over 200 novel small molecules, which they describe as five times more than every other player combined. Each discovery enriches the dataset and accelerates the next one. The output isn’t a research tool. It’s a molecule-generating engine with a proprietary library that doesn’t exist in any public database or AI training set. ### Use of Proceeds and Vision Generare plans to scale its molecule library 10x by 2027, growing from 200 to over 2,000 compounds with a long-term target of 10,000. The team will nearly double from 25 to roughly 50, hiring across computational biology, chemistry, synthetic biology, and engineering. Their thesis is direct: “Life has been writing for 3 billion years. 97% has never been read.” ### Market Context The global microbial genomics market is projected to grow from $2.5 billion in 2025 to $4.6 billion by 2030 at a 13% CAGR. Generare already partners with major pharmaceutical and agrochemical companies, though specific names haven’t been disclosed. As AI-driven drug discovery matures, the bottleneck is shifting from compute to novel training data, and that’s exactly what Generare produces. ## Lessons For Founders - **Regulatory compliance as moat, not burden.** Midas spent the time and money to get BaFin and MiCA compliance early. That’s now a distribution advantage across the entire EU that competitors need years to replicate. If you’re in a regulated market, the fastest path to defensibility might be through the paperwork, not around it. - **Data assets beat algorithms.** Both companies are building proprietary datasets that don’t exist anywhere else. Midas accumulates on-chain investment product data; Generare builds a molecular library from unexplored genomes. When your data can’t be scraped, purchased, or synthesized, your moat deepens with every unit of work. - **Returning investors signal more than new ones.** All three of Generare’s seed investors came back for the Series A. Repeat checks from insiders who’ve had 18 months of board-level visibility are a stronger signal than a marquee name writing a first check. - **Institutional credibility unlocks distribution.** Midas didn’t just raise from crypto funds. Franklin Templeton and Coinbase Ventures in the same cap table tells institutional buyers and retail platforms that both worlds consider this legitimate. Pick investors who open doors to your actual customers. - **Speed of output matters more than speed of founding.** Generare is three years old and claims to have characterized more novel molecules in one year than the rest of the field combined. Midas shipped $1.7 billion in tokenized assets within two years of founding. In both cases, the metric that mattered was output velocity, not how long the company had existed.